Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy

Strong NPM-139 safety and tolerability profile:-0 of 10 NPM-139 subjects experienced adverse events reported as treatment related-5 of 10 Wegovy subjects (control group) experienced adverse events reported as treatment related (gastrointestinal only, consistent with marketed GLP-1 therapies)Encoura…